Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 135

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 135
---
 as follows: $0.05 per unit sold in the base offering, or 0.5% of the gross proceeds of the offering, or $1,000,000 (or up to $1,150,000 if the overallotment option is exercised in full) in the aggregate, is payable upon the closing of this offering. Includes $0.30 per unit, or 3.0% of the gross proceeds of the offering, or $6,000,000 (or up to $6,900,000 if the underwriters’ over -allotment option is exercised in full) in the aggregate, of which 25.0% will be adjusted net of redemptions (i.e., for purposes of calculating the deferred underwriting commission net of redemptions, 25.0% of the deferred underwriting commissions will determined by the dollar amount that is product of (i) 3.0% multiplied by the product of the number of unredeemed public shares, multiplied by $10.00 and (ii) 25.0%), payable to the underwriters for deferred underwriting commissions to be placed in a trust account located in the United States as described herein. See also “ Underwriting ” for a description of compensation and other items of value payable to the underwriters. (3)If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our initial shareholders, directors, executive officers, advisors or their affiliates may purchase shares or public rights in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of ordinary shares subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See “ Proposed Business — Permitted Purchases of Our Securities .”

87

Capitalization The following table sets forth our capitalization at September30, 2024, and as adjusted to give effect to the filing of our amended and restated memorandum and articles of association, the sale of our 20,000,000 units in this offering for $200,000,000 (or $10.00 per unit) and the sale of 400,000 private units for $4,000,000 (or $10.00 per unit) and the application of the estimated